Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study
Abstract Background Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with favourable effects on CV disease, especially its high molecular weight (HMW) isoform. Body composition changes are d...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-020-02297-7 |
id |
doaj-57fa5655c0c64ea0aba3f37d52baaf03 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eric Toussirot Hubert Marotte Denis Mulleman Grégoire Cormier Fabienne Coury Philippe Gaudin Emmanuelle Dernis Christine Bonnet Richard Damade Jean-Luc Grauer Tassadit Ait Abdesselam Caroline Guillibert-Karras Frédéric Lioté Pascal Hilliquin Antoinette Sacchi Daniel Wendling Benoît Le Goff Marc Puyraveau Gilles Dumoulin |
spellingShingle |
Eric Toussirot Hubert Marotte Denis Mulleman Grégoire Cormier Fabienne Coury Philippe Gaudin Emmanuelle Dernis Christine Bonnet Richard Damade Jean-Luc Grauer Tassadit Ait Abdesselam Caroline Guillibert-Karras Frédéric Lioté Pascal Hilliquin Antoinette Sacchi Daniel Wendling Benoît Le Goff Marc Puyraveau Gilles Dumoulin Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study Arthritis Research & Therapy Adiponectin Cardiovascular risk Rheumatoid arthritis Tocilizumab Body composition |
author_facet |
Eric Toussirot Hubert Marotte Denis Mulleman Grégoire Cormier Fabienne Coury Philippe Gaudin Emmanuelle Dernis Christine Bonnet Richard Damade Jean-Luc Grauer Tassadit Ait Abdesselam Caroline Guillibert-Karras Frédéric Lioté Pascal Hilliquin Antoinette Sacchi Daniel Wendling Benoît Le Goff Marc Puyraveau Gilles Dumoulin |
author_sort |
Eric Toussirot |
title |
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study |
title_short |
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study |
title_full |
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study |
title_fullStr |
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study |
title_full_unstemmed |
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study |
title_sort |
increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study |
publisher |
BMC |
series |
Arthritis Research & Therapy |
issn |
1478-6362 |
publishDate |
2020-09-01 |
description |
Abstract Background Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with favourable effects on CV disease, especially its high molecular weight (HMW) isoform. Body composition changes are described in RA with various phenotypes including obesity. The effects of tocilizumab on serum adiponectin and body composition, especially fat mass, in patients with RA are not well determined. Methods Patients with active RA despite previous csDMARDs and/or bDMARDs and who were tocilizumab naïve were enrolled in a multicentre open-label study. They were evaluated at baseline, 1, 3, 6 and 12 months. Clinical assessment included body mass index (BMI) and anthropometric measurements. Lipid and metabolic parameters, serum adiponectin (total and HMW), leptin, resistin and ghrelin were measured at each time point. Body composition (lean mass, fat mass, % fat, fat in the android and gynoid regions) was evaluated at baseline, 6 and 12 months. Results One hundred seven patients were included. Both total and HMW adiponectin significantly increased from baseline to month 3, peaking respectively at month 3 (p = 0.0105) and month 1 (p < 0.0001), then declining progressively until month 6 to 12 and returning to baseline values. Significant elevation in HMW adiponectin persisted at month 6 (p = 0.001). BMI and waist circumference significantly increased at month 6 and 12, as well as lean mass at month 6 (p = 0.0097). Fat mass, percentage fat and android fat did not change over the study period. Lipid parameters (total cholesterol and LDL cholesterol) increased while glycaemia, insulin and HOMA-IR remained stable. Serum leptin, resistin and ghrelin did not change during follow-up. Conclusions Tocilizumab treatment in RA patients was associated with a significant increase in total and HMW adiponectin, especially at the onset of the treatment. Tocilizumab also induced a significant gain in lean mass, while fat mass did not change. These variations in adiponectin levels during tocilizumab treatment could have positive effects on the CV risk of RA patients. In addition, tocilizumab may have an anabolic impact on lean mass/skeletal muscle. Trial registration The ADIPRAT study was a phase IV open-label multicentre study retrospectively registered on ClinicalTrials.gov under the number NCT02843789 (date of registration: July 26, 2016). |
topic |
Adiponectin Cardiovascular risk Rheumatoid arthritis Tocilizumab Body composition |
url |
http://link.springer.com/article/10.1186/s13075-020-02297-7 |
work_keys_str_mv |
AT erictoussirot increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT hubertmarotte increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT denismulleman increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT gregoirecormier increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT fabiennecoury increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT philippegaudin increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT emmanuelledernis increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT christinebonnet increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT richarddamade increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT jeanlucgrauer increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT tassaditaitabdesselam increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT carolineguillibertkarras increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT fredericliote increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT pascalhilliquin increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT antoinettesacchi increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT danielwendling increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT benoitlegoff increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT marcpuyraveau increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy AT gillesdumoulin increasedhighmolecularweightadiponectinandleanmassduringtocilizumabtreatmentinpatientswithrheumatoidarthritisa12monthmulticentrestudy |
_version_ |
1724468101593956352 |
spelling |
doaj-57fa5655c0c64ea0aba3f37d52baaf032020-11-25T03:55:47ZengBMCArthritis Research & Therapy1478-63622020-09-0122111310.1186/s13075-020-02297-7Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre studyEric Toussirot0Hubert Marotte1Denis Mulleman2Grégoire Cormier3Fabienne Coury4Philippe Gaudin5Emmanuelle Dernis6Christine Bonnet7Richard Damade8Jean-Luc Grauer9Tassadit Ait Abdesselam10Caroline Guillibert-Karras11Frédéric Lioté12Pascal Hilliquin13Antoinette Sacchi14Daniel Wendling15Benoît Le Goff16Marc Puyraveau17Gilles Dumoulin18INSERM CIC-1431, CHU de Besançon, Centre d’Investigation Clinique BiothérapieINSERM 1059, Université de Lyon, Saint-Etienne; Rhumatologie CHU de Saint-Etienne; CIC-1408, CHU de Saint-EtienneRhumatologie CHU de ToursRhumatologie Centre Hospitalier Départemental VendéeRhumatologie Hospices Civils de Lyon, INSERM UMR1033, Université Lyon 1Rhumatologie CHU de GrenobleRhumatologie Centre HospitalierRhumatologie CHU de LimogesRhumatologie Centre HospitalierRhumatologie Centre HospitalierRhumatologie Centre HospitalierRhumatologie Hôpital St JosephRhumatologie Hôpital Lariboisière AP-HP Paris, Université de ParisRhumatologie Centre Hospitalier Sud FrancilienRhumatologie Centre hospitalier Mantes la JolieCHU de Besançon, Rhumatologie, Pôle PACTE (Pathologies Aiguës Chroniques Transplantation Éducation)Rhumatologie CHU de NantesINSERM CIC-1431, CHU de Besançon, Centre d’Investigation Clinique BiothérapieLaboratoire de Biochimie Médicale, UF de Biochimie Endocrinienne et Métabolique, CHU de Besançon; EA 3920 Marqueurs pronostiques et facteurs de régulation des pathologies cardiaques et vasculaires, Université de Bourgogne Franche ComtéAbstract Background Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with favourable effects on CV disease, especially its high molecular weight (HMW) isoform. Body composition changes are described in RA with various phenotypes including obesity. The effects of tocilizumab on serum adiponectin and body composition, especially fat mass, in patients with RA are not well determined. Methods Patients with active RA despite previous csDMARDs and/or bDMARDs and who were tocilizumab naïve were enrolled in a multicentre open-label study. They were evaluated at baseline, 1, 3, 6 and 12 months. Clinical assessment included body mass index (BMI) and anthropometric measurements. Lipid and metabolic parameters, serum adiponectin (total and HMW), leptin, resistin and ghrelin were measured at each time point. Body composition (lean mass, fat mass, % fat, fat in the android and gynoid regions) was evaluated at baseline, 6 and 12 months. Results One hundred seven patients were included. Both total and HMW adiponectin significantly increased from baseline to month 3, peaking respectively at month 3 (p = 0.0105) and month 1 (p < 0.0001), then declining progressively until month 6 to 12 and returning to baseline values. Significant elevation in HMW adiponectin persisted at month 6 (p = 0.001). BMI and waist circumference significantly increased at month 6 and 12, as well as lean mass at month 6 (p = 0.0097). Fat mass, percentage fat and android fat did not change over the study period. Lipid parameters (total cholesterol and LDL cholesterol) increased while glycaemia, insulin and HOMA-IR remained stable. Serum leptin, resistin and ghrelin did not change during follow-up. Conclusions Tocilizumab treatment in RA patients was associated with a significant increase in total and HMW adiponectin, especially at the onset of the treatment. Tocilizumab also induced a significant gain in lean mass, while fat mass did not change. These variations in adiponectin levels during tocilizumab treatment could have positive effects on the CV risk of RA patients. In addition, tocilizumab may have an anabolic impact on lean mass/skeletal muscle. Trial registration The ADIPRAT study was a phase IV open-label multicentre study retrospectively registered on ClinicalTrials.gov under the number NCT02843789 (date of registration: July 26, 2016).http://link.springer.com/article/10.1186/s13075-020-02297-7AdiponectinCardiovascular riskRheumatoid arthritisTocilizumabBody composition |